Completed PHASE2 INTERVENTIONAL 1-arm NCT01719159

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)

Sponsor: Anders Svenningsson

Conditions Progressive Multiple Sclerosis

Interventions Rituximab

Updated 5 times since 2017 Last updated: Nov 18, 2016 Started: Nov 30, 2009 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Progressive Multiple Sclerosis and is currently completed. Anders Svenningsson leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anders Svenningsson
Västerbotten County Council, Sweden

Data source: Umeå University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Umeå, Sweden
• Uppsala, Sweden